US Patent

US10131667 — Substituted tricyclic compounds as FGFR inhibitors

Method of Use · Assigned to Incyte Corp · Expires 2034-04-17 · 8y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects pharmaceutical compositions of tricyclic compounds that inhibit FGFR enzymes and are used to treat FGFR-associated diseases such as cancer.

USPTO Abstract

The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2809 — Pemazyre
U-2809 — Pemazyre
U-2809 — Pemazyre

Patent Metadata

Patent number
US10131667
Jurisdiction
US
Classification
Method of Use
Expires
2034-04-17
Drug substance claim
No
Drug product claim
No
Assignee
Incyte Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.